Our Mission and what we do

We Are OncoAlert
A network of Cancer Care professionals (Medical, Radiation & Surgical Oncologists, along with Cancer Scientists, Oncology nurses and patient advocates). A global network with the majority of our faculty coming from the US and Europe, but quickly extending.
Our Goals
1. Promoting quality oncology education in order to reduce global disparities
2. Amplify and highlight the needs and concerns of our Patient Advocates
3. Inform and amplify the latest in Oncology
OncoAlert was founded in March 2019 as an informal network, with no money exchanged or accepted. All work contributions made by OncoAlert faculty have been provided voluntarily, without any form of compensation. All costs associated with OncoAlert were fully financed by Gilbert Morgan, MD (Founder and Director of OncoAlert).
In June 2023, OncoAlert transitioned into a nonprofit NGO (Non-Governmental Organization) and began funding its activities, initiatives, and fellowships through educational grants and support from collaborators. While the network maintains the same mission and mandates, this shift was essential to support its growth (as the Catalyst Fellowships) and achieve the desired global impact as an NGO. Since June 2023, Gilbert Morgan, MD, has assumed the role of Executive Director of OncoAlert (full-time), focusing on the continued development of OncoAlert and ensuring the success of ongoing initiatives and flagship events.
A network of Cancer Care professionals (Medical, Radiation & Surgical Oncologists, along with Cancer Scientists, Oncology nurses and patient advocates). A global network with the majority of our faculty coming from the US and Europe, but quickly extending.
Our Goals
1. Promoting quality oncology education in order to reduce global disparities
2. Amplify and highlight the needs and concerns of our Patient Advocates
3. Inform and amplify the latest in Oncology
OncoAlert was founded in March 2019 as an informal network, with no money exchanged or accepted. All work contributions made by OncoAlert faculty have been provided voluntarily, without any form of compensation. All costs associated with OncoAlert were fully financed by Gilbert Morgan, MD (Founder and Director of OncoAlert).
In June 2023, OncoAlert transitioned into a nonprofit NGO (Non-Governmental Organization) and began funding its activities, initiatives, and fellowships through educational grants and support from collaborators. While the network maintains the same mission and mandates, this shift was essential to support its growth (as the Catalyst Fellowships) and achieve the desired global impact as an NGO. Since June 2023, Gilbert Morgan, MD, has assumed the role of Executive Director of OncoAlert (full-time), focusing on the continued development of OncoAlert and ensuring the success of ongoing initiatives and flagship events.
Dr. Gil Morgan (Director and Network Representative)
Originally from Texas but due to all the strange turns of life ended moving and practicing medicine in Sweden for over a decade. Specialized in Clinical Oncology (Medical & Radiation Oncology) with a strong emphasis on Cancer Prevention and Targeted Therapeutics.
Originally from Texas but due to all the strange turns of life ended moving and practicing medicine in Sweden for over a decade. Specialized in Clinical Oncology (Medical & Radiation Oncology) with a strong emphasis on Cancer Prevention and Targeted Therapeutics.
Our OncoAlert Faculty & Strongest Supporters

Dr. Toni Choueiri
Dr. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and President of the Medical Staff at Dana-Farber. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, the GU Steering Committee (GUSC) Task Force of the National Cancer Institute (NCI), and is Chairman of the Medical and Scientific Steering Committee of the Kidney Cancer Association.
Dr. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and President of the Medical Staff at Dana-Farber. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, the GU Steering Committee (GUSC) Task Force of the National Cancer Institute (NCI), and is Chairman of the Medical and Scientific Steering Committee of the Kidney Cancer Association.

Dr. Julie R Gralow
Dr. Gralow is the Chief Medical Officer (CMO) and Executive Vice President of ASCO, and brings to her role deep expertise in patient care, research, education, and global health.
Dr. Gralow is the Chief Medical Officer (CMO) and Executive Vice President of ASCO, and brings to her role deep expertise in patient care, research, education, and global health.

Dr. Solange Peters
Dr. Peters is President of the European Society for Medical Oncology
She is also currently in charge of teaching and patient care in the area of medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University.
Dr. Peters is President of the European Society for Medical Oncology
She is also currently in charge of teaching and patient care in the area of medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University.

Dr. Lena Sharp
Dr. Sharp is the past President of the European Oncology Nurses Society. Head of the Regional Cancer Center, Stockholm, Sweden. She was previously the Chief Nursing Officer and Patient Safety Coordinator at the Department of Oncology, Karolinska University Hospital and has a long experience in cancer nursing, clinical work, leadership, teaching and research. Lena main research focus is Health Care Communication and Patient Safety. Lena has a Ph D from Karolinska Institute.
Dr. Sharp is the past President of the European Oncology Nurses Society. Head of the Regional Cancer Center, Stockholm, Sweden. She was previously the Chief Nursing Officer and Patient Safety Coordinator at the Department of Oncology, Karolinska University Hospital and has a long experience in cancer nursing, clinical work, leadership, teaching and research. Lena main research focus is Health Care Communication and Patient Safety. Lena has a Ph D from Karolinska Institute.

Dr. Andrés Cervantes
Incoming President of the European Society for Medical Oncology
Professor of Medicine at the University of Valencia, Spain.
Dr. Cervantes serves as Head of the Department of Medical Oncology at the University Hospital in Valencia

Dr. Tom Powles
Thomas Powles is a Professor of Urology Cancer at the University of London, a position he has held since 2012, and has been the Director of Barts Cancer Centre since 2017. Barts is one of the largest cancer centers in the UK, treating over 4,000 new cancer patients annually and designated as a CRUK Major Cancer Centre. He trained as an oncologist at Imperial College and is a leading figure in cancer care and research.
Thomas Powles is a Professor of Urology Cancer at the University of London, a position he has held since 2012, and has been the Director of Barts Cancer Centre since 2017. Barts is one of the largest cancer centers in the UK, treating over 4,000 new cancer patients annually and designated as a CRUK Major Cancer Centre. He trained as an oncologist at Imperial College and is a leading figure in cancer care and research.

Dr. Hope Rugo
Dr. Rugo is a professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she is also the director of Breast Oncology and Clinical Trials Education.

Dr. Henning Willers
Dr. Willers earned his M.D. from the University of Hamburg Medical School in 1994 and initially trained in radiation oncology in Germany. He then moved to Boston to conduct research on DNA repair under Dr. Simon Powell before completing his residency in radiation oncology at Massachusetts General Hospital (MGH) in 2005. After three years at Boston Medical Center, he returned to MGH to join the Thoracic Radiation Oncology Program. Dr. Willers manages a busy clinical practice focused on thoracic cancers while also conducting research in precision radiation medicine, aiming to improve lung cancer treatment by integrating biological therapies with high-precision radiation to enhance cure rates without complications.
Dr. Willers earned his M.D. from the University of Hamburg Medical School in 1994 and initially trained in radiation oncology in Germany. He then moved to Boston to conduct research on DNA repair under Dr. Simon Powell before completing his residency in radiation oncology at Massachusetts General Hospital (MGH) in 2005. After three years at Boston Medical Center, he returned to MGH to join the Thoracic Radiation Oncology Program. Dr. Willers manages a busy clinical practice focused on thoracic cancers while also conducting research in precision radiation medicine, aiming to improve lung cancer treatment by integrating biological therapies with high-precision radiation to enhance cure rates without complications.

Dr. Don Dizon
oncologist who specializes in women's cancers. He is the director of women's cancers at Lifespan Cancer Institute and director of medical oncology at Rhode Island Hospital. He is also a professor of medicine at The Warren Alpert Medical School of Brown University.
oncologist who specializes in women's cancers. He is the director of women's cancers at Lifespan Cancer Institute and director of medical oncology at Rhode Island Hospital. He is also a professor of medicine at The Warren Alpert Medical School of Brown University.

Dr. Eleni Efstathiou
Section Chief of GenitoUrinary Medical Oncology at Houston Methodist Cancer Center, renowned for her groundbreaking translational research in prostate cancer. With clinical practices in both the U.S. and Europe, she brings extensive expertise across the genitourinary oncology spectrum. Her research focuses on novel therapeutics and precision medicine, aiming to develop marker-driven treatment strategies for prostate cancer while studying genomic and non-genomic resistance pathways. Dr. Efstathiou is dedicated to combining academic research with precision care to enhance treatment planning, patient care, and therapeutic advancements.
Section Chief of GenitoUrinary Medical Oncology at Houston Methodist Cancer Center, renowned for her groundbreaking translational research in prostate cancer. With clinical practices in both the U.S. and Europe, she brings extensive expertise across the genitourinary oncology spectrum. Her research focuses on novel therapeutics and precision medicine, aiming to develop marker-driven treatment strategies for prostate cancer while studying genomic and non-genomic resistance pathways. Dr. Efstathiou is dedicated to combining academic research with precision care to enhance treatment planning, patient care, and therapeutic advancements.

Dr. Axel Merseburger
Chairman of the Department of Urology at Campus Lübeck, University Hospital Schleswig-Holstein, Germany. He earned his medical degree from Hannover Medical School in 2002, following an academic research program in Washington, D.C., where he completed his M.D. thesis. He completed his surgical and urological residency at the University of Tübingen, Germany, and was a Research Fellow at the Miller School of Medicine in Miami in 2006. After joining Hannover Medical School in 2008, he became an Associate Professor in 2009 and a full Professor in 2012. Board certified in urology, Professor Merseburger is an active member of various national and international urological and oncological associations.
Chairman of the Department of Urology at Campus Lübeck, University Hospital Schleswig-Holstein, Germany. He earned his medical degree from Hannover Medical School in 2002, following an academic research program in Washington, D.C., where he completed his M.D. thesis. He completed his surgical and urological residency at the University of Tübingen, Germany, and was a Research Fellow at the Miller School of Medicine in Miami in 2006. After joining Hannover Medical School in 2008, he became an Associate Professor in 2009 and a full Professor in 2012. Board certified in urology, Professor Merseburger is an active member of various national and international urological and oncological associations.

Dr. Darcy Burbage
Director at Large at Oncology Nursing Society
Oncology Clinical Nurse specialist & Oncology Nursing Advocate
Director at Large at Oncology Nursing Society
Oncology Clinical Nurse specialist & Oncology Nursing Advocate

Dr. Neeraj Agarwal
Profesor of medicine/physician and an investigator at the Huntsman Cancer Institute (HCI), University of Utah. At the HCI, he directs the Genitourinary Oncology (GU) Program, the Center of Investigational Therapeutics (CIT), co-leads the Experimental Therapeutic Program (one of the four cancer center support grant programs at the HCI), and serves on the cabinet of the Director of HCI.
Profesor of medicine/physician and an investigator at the Huntsman Cancer Institute (HCI), University of Utah. At the HCI, he directs the Genitourinary Oncology (GU) Program, the Center of Investigational Therapeutics (CIT), co-leads the Experimental Therapeutic Program (one of the four cancer center support grant programs at the HCI), and serves on the cabinet of the Director of HCI.

Dr. Christine Lovly
- Associate Professor of Medicine at Vanderbilt University. Her research involves the development of novel treatment strategies for ALK positive lung cancer.

Dr. Charles Swanton
Professor Charles Swanton FRCP BSc PhD is a clinician scientist, focusing his work on understanding the challenges inherent in the management of metastatic cancer and their drug resistant and incurable nature.

Dr. Fumiko Chino
Dr. Chino is a radiation oncologist at Memorial Sloan-Kettering Cancer Center, describes to host Jack West the impact of a mother as a successful radiation oncologist, & the many struggles of serving as a caregiver to a young adult spouse with cancer.
Dr. Chino is a radiation oncologist at Memorial Sloan-Kettering Cancer Center, describes to host Jack West the impact of a mother as a successful radiation oncologist, & the many struggles of serving as a caregiver to a young adult spouse with cancer.

Dr. Matteo Lambertini
Dr. Lambertini is an adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital – University of Genova in Genova (Italy). He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research.
Dr. Lambertini is an adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital – University of Genova in Genova (Italy). He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research.

Ginny Mason RN
Nurse Mason is the Executive Director of the Inflammatory Breast Cancer Research Foundation (ibcRF), a grassroots advocacy organization dedicated to advancing inflammatory breast cancer (IBC) research as well as increasing awareness of IBC in the medical and lay communities.
Nurse Mason is the Executive Director of the Inflammatory Breast Cancer Research Foundation (ibcRF), a grassroots advocacy organization dedicated to advancing inflammatory breast cancer (IBC) research as well as increasing awareness of IBC in the medical and lay communities.

Dr . Aleix Prat
Head of the Medical Oncology Department of the Hospital Clínic Barcelona (Spain), Associate Professor at the University of Barcelona and Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at IDIBAPS.
Head of the Medical Oncology Department of the Hospital Clínic Barcelona (Spain), Associate Professor at the University of Barcelona and Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at IDIBAPS.

Dr. Erika Hamilton
Dr. Hamilton cares for patients with breast and gynecologic cancer. As the director of the breast cancer and gynecologic cancer research program at Sarah Cannon Research Institute, she oversees the program and the clinical trial menu for these cancers across the Sarah Cannon network.
Dr. Hamilton cares for patients with breast and gynecologic cancer. As the director of the breast cancer and gynecologic cancer research program at Sarah Cannon Research Institute, she oversees the program and the clinical trial menu for these cancers across the Sarah Cannon network.

Dr. Hans Hammers
Oncologist in Dallas, Texas, affiliated with University of Texas Southwestern Medical Center
Leaders in Kidney Cancer Research
Oncologist in Dallas, Texas, affiliated with University of Texas Southwestern Medical Center
Leaders in Kidney Cancer Research

Dr. Ane Gerda Zahl Eriksson
Senior consultant at the Norwegian Radium Hospital, Oslo University Hospital, where she leads the endometrial cancer and gynecologic sarcoma team. She earned her medical degree from the Medical University of Warsaw, completed her residency at Oslo University Hospital, and pursued a fellowship in Gynecologic Oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Eriksson specializes in advanced minimally invasive surgery and radical procedures for gynecologic cancers, particularly ovarian cancer. Passionate about surgical education, she founded and chairs the Advanced Course in Cytoreductive Surgery for Ovarian Cancer at Oslo University Hospital.
Senior consultant at the Norwegian Radium Hospital, Oslo University Hospital, where she leads the endometrial cancer and gynecologic sarcoma team. She earned her medical degree from the Medical University of Warsaw, completed her residency at Oslo University Hospital, and pursued a fellowship in Gynecologic Oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Eriksson specializes in advanced minimally invasive surgery and radical procedures for gynecologic cancers, particularly ovarian cancer. Passionate about surgical education, she founded and chairs the Advanced Course in Cytoreductive Surgery for Ovarian Cancer at Oslo University Hospital.

Dr. Enrique Grande
Director of the Medical Oncology Program and Clinical Research Lead at MD Anderson Cancer Center Madrid, where he focuses on advancing cancer treatment and research. A founding partner of the Spanish Group of Orphan and Rare Tumors (GETHI), he also serves on the boards of several oncology organizations, including the Spanish Agency for Medicines (Aemps) and the Spanish Group of Neuroendocrine Tumors (GETNE). Dr. Grande earned his PhD cum laude in 2013 from the University of Alcalá, Madrid, and has nearly a decade of clinical experience at Ramon y Cajal University Hospital, where he led Clinical and Translational Research in Medical Oncology, contributing significantly to the field.
Director of the Medical Oncology Program and Clinical Research Lead at MD Anderson Cancer Center Madrid, where he focuses on advancing cancer treatment and research. A founding partner of the Spanish Group of Orphan and Rare Tumors (GETHI), he also serves on the boards of several oncology organizations, including the Spanish Agency for Medicines (Aemps) and the Spanish Group of Neuroendocrine Tumors (GETNE). Dr. Grande earned his PhD cum laude in 2013 from the University of Alcalá, Madrid, and has nearly a decade of clinical experience at Ramon y Cajal University Hospital, where he led Clinical and Translational Research in Medical Oncology, contributing significantly to the field.

Dr. Evandro de Azambuja
Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium.
Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium.

Dr. Helena Ullgren
Specialist Nurse Oncology and palliative care, PhD
Karolinska University Hospital
President Elect of European Oncology Nurses Society
Specialist Nurse Oncology and palliative care, PhD
Karolinska University Hospital
President Elect of European Oncology Nurses Society

Dr. Daniel Castellano
Medical oncologist and the head of the Genitourinary Tumor Department at Hospital 12 de Octubre in Madrid, where he specializes in researching genitourinary tumors. In addition to his clinical work, he serves as an executive member of the GUARD consortium, contributing to collaborative efforts aimed at advancing the understanding and treatment of genitourinary cancers.
Medical oncologist and the head of the Genitourinary Tumor Department at Hospital 12 de Octubre in Madrid, where he specializes in researching genitourinary tumors. In addition to his clinical work, he serves as an executive member of the GUARD consortium, contributing to collaborative efforts aimed at advancing the understanding and treatment of genitourinary cancers.

Dr. Mark Lewis
Dr. Lewis is the Director of Gastrointestinal Oncology,
Intermountain Healthcare. Intermountain Medical Oncology
Dr. Lewis is the Director of Gastrointestinal Oncology,
Intermountain Healthcare. Intermountain Medical Oncology

Dr. Vivek Subbiah
Dr. Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (SCRI), a role he assumed in 2023. He oversees nine drug development units and leads the expansion of early-phase programs across SCRI’s extensive research network, which includes over 1,300 physicians at more than 250 locations in 24 states. Prior to joining SCRI, Dr. Subbiah spent nearly 15 years at the University of Texas MD Anderson Cancer Center, where he held key leadership roles, including Executive Director of Medical Oncology Research and Clinical Medical Director in the Division of Cancer Medicine, managing operations for the Phase I program.
Dr. Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (SCRI), a role he assumed in 2023. He oversees nine drug development units and leads the expansion of early-phase programs across SCRI’s extensive research network, which includes over 1,300 physicians at more than 250 locations in 24 states. Prior to joining SCRI, Dr. Subbiah spent nearly 15 years at the University of Texas MD Anderson Cancer Center, where he held key leadership roles, including Executive Director of Medical Oncology Research and Clinical Medical Director in the Division of Cancer Medicine, managing operations for the Phase I program.

Dr. Sherene Loi
Medical Oncologist specialised in breast cancer treatment as well as clinician scientist with expertise in genomics, immunology and drug development. Her work is focused on developing new therapeutic approaches that may improve outcomes of breast cancer patients.
Medical Oncologist specialised in breast cancer treatment as well as clinician scientist with expertise in genomics, immunology and drug development. Her work is focused on developing new therapeutic approaches that may improve outcomes of breast cancer patients.

Dr. Icro Meattini
Doctor Meattini is an Associate Professor at the Department of Clinical and Experimental Biomedical Sciences of the University of Florence (Florence, Italy), Icro Meattini works as Clinical Oncologist since 2011 at the Radiation Oncology Unit of the Oncology Department at the Florence University Hospital, where is responsible for the Outpatient Clinics Unit, Clinical Trials Unit, and leader of the Clinical Oncology Group of the Breast Cancer Multidisciplinary Team. Active member of the European Society for Radiation Oncology (ESTRO), the European Organisation for Research and Treatment of Cancer (EORTC), and the Italian Association for Radiation and Clinical Oncology (AIRO).
Doctor Meattini is an Associate Professor at the Department of Clinical and Experimental Biomedical Sciences of the University of Florence (Florence, Italy), Icro Meattini works as Clinical Oncologist since 2011 at the Radiation Oncology Unit of the Oncology Department at the Florence University Hospital, where is responsible for the Outpatient Clinics Unit, Clinical Trials Unit, and leader of the Clinical Oncology Group of the Breast Cancer Multidisciplinary Team. Active member of the European Society for Radiation Oncology (ESTRO), the European Organisation for Research and Treatment of Cancer (EORTC), and the Italian Association for Radiation and Clinical Oncology (AIRO).

Dr. Stephen V. Liu
Dr. Stephen V. Liu is an Assistant Professor of Medicine and a practicing thoracic medical oncologist at the Lombardi Comprehensive Cancer Center at Georgetown University.
Dr. Stephen V. Liu is an Assistant Professor of Medicine and a practicing thoracic medical oncologist at the Lombardi Comprehensive Cancer Center at Georgetown University.

Dr. Elisabeth de Vries
Professor of Medical Oncology at the University Medical Center Groningen, Groningen, the Netherlands. She is involved in patient care, teaching, and research. Her focus is on interdisciplinary, translational research, aiming for personalized medicine.
Professor of Medical Oncology at the University Medical Center Groningen, Groningen, the Netherlands. She is involved in patient care, teaching, and research. Her focus is on interdisciplinary, translational research, aiming for personalized medicine.

Dr. Gilberto Lopes
Dr. Lopes is a medical oncologist, is medical director for international programs and associate director for global oncology at the Sylvester Comprehensive Cancer Center and associate professor of clinical medicine at the University of Miami in Florida.
Dr. Lopes is a medical oncologist, is medical director for international programs and associate director for global oncology at the Sylvester Comprehensive Cancer Center and associate professor of clinical medicine at the University of Miami in Florida.

Janet Freeman-Daily
Patient Advocate and a 4+ year NSCLC survivor, “kept alive,” as she says, by clinical trials. In her previous career, Janet was an aerospace systems engineer where, among other things, she learned to be a technical translator. She now brings that same experience and science to lung cancer writing, blogging, public speaking, as well as collaborating with other patients, care partners, advocates, healthcare providers and researchers.
Patient Advocate and a 4+ year NSCLC survivor, “kept alive,” as she says, by clinical trials. In her previous career, Janet was an aerospace systems engineer where, among other things, she learned to be a technical translator. She now brings that same experience and science to lung cancer writing, blogging, public speaking, as well as collaborating with other patients, care partners, advocates, healthcare providers and researchers.

Dr. Fabrice Barlesi
General Director of Gustave Roussy
Doctor Barlesi is a Professor of Medicine at the University of Aix-Marseille. He has been head of the Multidisciplinary Oncology and Innovative Therapies Department of the Nord Hospital in Marseille (Marseille Public Hospitals) and the Marseille Centre for Early Trials in Oncology (CLIP2) which were established by him
General Director of Gustave Roussy
Doctor Barlesi is a Professor of Medicine at the University of Aix-Marseille. He has been head of the Multidisciplinary Oncology and Innovative Therapies Department of the Nord Hospital in Marseille (Marseille Public Hospitals) and the Marseille Centre for Early Trials in Oncology (CLIP2) which were established by him

Julia Maues
Julia is a metastatic breast cancer survivor and advocate, committed to contributing with patients, researchers, clinicians, drugmakers, and other stakeholders to improve the lives of women and men affected by the disease.
CoCreator of GRASP
Julia is a metastatic breast cancer survivor and advocate, committed to contributing with patients, researchers, clinicians, drugmakers, and other stakeholders to improve the lives of women and men affected by the disease.
CoCreator of GRASP

- Dr. Jonathan Trent

Dr. Jack West
Executive Director of Employer Strategy; Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research. City of Hope
Executive Director of Employer Strategy; Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research. City of Hope

Dr. Miriam Knoll
Radiation Oncologist, Forbes Health Contributor, JOWMA President. Advanced Radiation Oncology Services at Montefiore Nyack Hospital, New York
Radiation Oncologist, Forbes Health Contributor, JOWMA President. Advanced Radiation Oncology Services at Montefiore Nyack Hospital, New York

Dr. Brendon Stiles
Cardiothoracic surgeon at NewYork-Presbyterian/Weill Cornell Medical Center
Dr. Stiles is the chair of the Lung Cancer Research Foundation's board directors
Cardiothoracic surgeon at NewYork-Presbyterian/Weill Cornell Medical Center
Dr. Stiles is the chair of the Lung Cancer Research Foundation's board directors

Dr. Sara Tolaney
Dr. Tolaney is an Assistant Professor of Medicine at Harvard Medical School and Associate Director for the Susan F Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women's Cancer Center.
Dr. Tolaney is an Assistant Professor of Medicine at Harvard Medical School and Associate Director for the Susan F Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women's Cancer Center.

Dr. Andreas Charalambous
Dr. Andreas Charalambous, RN, PhD (Oncology Nursing), has a clinical background in cancer care and has worked clinically and academically in Cyprus, U.K and Finland. He holds an Assistant Professor’s position of Oncology and Palliative Care at the Cyprus University of Technology and a Docent’s position at University of Turku (Finland). He is an EONS Executive Board Member since 2013 and was elected as President-Elect in 2017.
Dr. Andreas Charalambous, RN, PhD (Oncology Nursing), has a clinical background in cancer care and has worked clinically and academically in Cyprus, U.K and Finland. He holds an Assistant Professor’s position of Oncology and Palliative Care at the Cyprus University of Technology and a Docent’s position at University of Turku (Finland). He is an EONS Executive Board Member since 2013 and was elected as President-Elect in 2017.

Dr. Narjust Duma
Doctor Duma is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care. She is a medical oncologist with clinical and research focus on thoracic malignancies.
Co Founder of Latinas in medicine
Doctor Duma is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care. She is a medical oncologist with clinical and research focus on thoracic malignancies.
Co Founder of Latinas in medicine

Dr. Fabrice André
Fabrice André MD, PhD, is an oncologist based at Gustave Roussy Cancer Cancer, Villejuif, France. He is Professor of Medicine at University Paris Saclay. His BCRF research focuses on the characterisation of molecular alterations in metastatic breast cancers.
Fabrice André MD, PhD, is an oncologist based at Gustave Roussy Cancer Cancer, Villejuif, France. He is Professor of Medicine at University Paris Saclay. His BCRF research focuses on the characterisation of molecular alterations in metastatic breast cancers.

Dr. Anne Marie Baird
president of Lung Cancer Europe (LuCE). LuCE is a non-profit umbrella organization that aims to provide a voice for people impacted by lung cancer in Europe.
Doctor Baird is a molecular biologist with research interests in inflammation, epigenetics, drug resistance and disease biomarkers. She is currently a Research Fellow in Trinity College Dublin and a Visiting Research Fellow in Queensland University of Technology.
president of Lung Cancer Europe (LuCE). LuCE is a non-profit umbrella organization that aims to provide a voice for people impacted by lung cancer in Europe.
Doctor Baird is a molecular biologist with research interests in inflammation, epigenetics, drug resistance and disease biomarkers. She is currently a Research Fellow in Trinity College Dublin and a Visiting Research Fellow in Queensland University of Technology.

Dr. Sumanta Pal
Internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancers. He is co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.
Internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancers. He is co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.

Dr. Stephanie Graff
Doctor Graff is a medical oncology specialist in Overland Park, KS. She currently practices at Sarah Cannon Cancer Institute at Menorah Medical Center and is affiliated with Research Medical Center.
Doctor Graff is a medical oncology specialist in Overland Park, KS. She currently practices at Sarah Cannon Cancer Institute at Menorah Medical Center and is affiliated with Research Medical Center.

Dr. Ravindran Kanesvaran
Doctor Kanesvaran is a Senior Consultant and Deputy Head of the Division of Medical Oncology of the National Cancer Centre Singapore and Medical Director of NCCS@ SKH Oncology. He is also an Associate Professor at Duke-NUS Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is the Program Director of the Medical Oncology Senior Residency Program.
Doctor Kanesvaran is a Senior Consultant and Deputy Head of the Division of Medical Oncology of the National Cancer Centre Singapore and Medical Director of NCCS@ SKH Oncology. He is also an Associate Professor at Duke-NUS Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is the Program Director of the Medical Oncology Senior Residency Program.

Dr. Pilar Garrido
Doctor Garrido is Associate Professor of Medical Oncology at Universidad de Alcalá and serves as Head of the Thoracic Tumours Section in the Medical Oncology Department at the University Hospital Ramón y Cajal in Madrid, Spain.
Doctor Garrido is Associate Professor of Medical Oncology at Universidad de Alcalá and serves as Head of the Thoracic Tumours Section in the Medical Oncology Department at the University Hospital Ramón y Cajal in Madrid, Spain.

Dr. Daniel Heng
Dr. Heng is a Staff Medical Oncologist at the Tom Baker Cancer Center in Calgary. Alberta and a Clinical Professor of Medicine at the University of Calgary .
Dr. Heng is a Staff Medical Oncologist at the Tom Baker Cancer Center in Calgary. Alberta and a Clinical Professor of Medicine at the University of Calgary .

Dr. Marina Garassino
Dr. Garassino is the head of the thoracic oncology unit at the National Cancer Institute of Milan, where her principle area of research is thoracic malignancies (lung cancer, mesothelioma, thymic malignancies).
Dr. Garassino is the head of the thoracic oncology unit at the National Cancer Institute of Milan, where her principle area of research is thoracic malignancies (lung cancer, mesothelioma, thymic malignancies).

Dr. Petros Grivas
Dr. Grivas is a board-certified medical oncologist who specializes in treating patients with genitourinary cancers, such as bladder cancer and prostate cancer.
Dr. Grivas serves as the director of University of Washington Medicine’s Genitourinary Cancers Program, giving frequent lectures, educating other oncologists and trainees and publishing novel research. He also conducts clinical trials, one of which led to the FDA approval of new drugs for bladder and urothelial cancer.
Dr. Grivas is a board-certified medical oncologist who specializes in treating patients with genitourinary cancers, such as bladder cancer and prostate cancer.
Dr. Grivas serves as the director of University of Washington Medicine’s Genitourinary Cancers Program, giving frequent lectures, educating other oncologists and trainees and publishing novel research. He also conducts clinical trials, one of which led to the FDA approval of new drugs for bladder and urothelial cancer.

Dr. Cathy Eng
Medical Oncology Specialist at the Vanderbilt-Ingram Cancer Center.
Doctor Eng is a Professor of Medicine, Hematology and Oncology, and is the Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program.
Medical Oncology Specialist at the Vanderbilt-Ingram Cancer Center.
Doctor Eng is a Professor of Medicine, Hematology and Oncology, and is the Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program.

Dr. Pashtoon Kasi
Doctor Kasi is a Clinical Assistant Professor of Internal Medicine - Hematology, Oncology and Blood and Marrow Transplantation. His research interests are in gastrointestinal cancers with a recent primary focus on colorectal cancers.
Doctor Kasi is a Clinical Assistant Professor of Internal Medicine - Hematology, Oncology and Blood and Marrow Transplantation. His research interests are in gastrointestinal cancers with a recent primary focus on colorectal cancers.

Dr. Andrea Apolo
Doctor Apolo is a meedical oncologist specialized in bladder cancer research. She is an investigator in the NCI's GU malignancies branch and head of the bladder cancer section.
Doctor Apolo is a meedical oncologist specialized in bladder cancer research. She is an investigator in the NCI's GU malignancies branch and head of the bladder cancer section.

Dr. Sanjay Popat
Doctor Popat is a Professor & Consultant Thoracic Medical Oncologist at The Royal Marsden and Honorary Clinical Senior Lecturer in the Molecular Genetics and Genomics Group at the National Heart and Lung Institute, Imperial College London.
Doctor Popat is a Professor & Consultant Thoracic Medical Oncologist at The Royal Marsden and Honorary Clinical Senior Lecturer in the Molecular Genetics and Genomics Group at the National Heart and Lung Institute, Imperial College London.

Ivy Elkins
Ivy is a Lung Cancer Patient Advocatehas served as a consumer reviewer for the Department of Defense Lung Cancer Research Program, completed the AACR Scientist-Survivor program, acted as faculty for the ASCO/AACR Methods in Clinical Cancer Research Workshop, and participated in the program committee for IASLC’s Chicago Multidisciplinary Symposium in Thoracic Oncology.
CoFounder of EGFRResisters
Ivy is a Lung Cancer Patient Advocatehas served as a consumer reviewer for the Department of Defense Lung Cancer Research Program, completed the AACR Scientist-Survivor program, acted as faculty for the ASCO/AACR Methods in Clinical Cancer Research Workshop, and participated in the program committee for IASLC’s Chicago Multidisciplinary Symposium in Thoracic Oncology.
CoFounder of EGFRResisters

Johan de Munter RN
Assistant Nurse Manager Cancer Center, University Hospital Ghent & President-Elect, European Oncology Nursing Society
Assistant Nurse Manager Cancer Center, University Hospital Ghent & President-Elect, European Oncology Nursing Society

Dr. Charu Aggarwal
Doctor Aggarwal is the Leslye Heisler Assistant Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania’s Perelman School of Medicine. She is an active member of the Abramson Cancer Center (ACC) where she serves as Physician Leader for the clinical research program for Airways Malignancies.
Doctor Aggarwal is the Leslye Heisler Assistant Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania’s Perelman School of Medicine. She is an active member of the Abramson Cancer Center (ACC) where she serves as Physician Leader for the clinical research program for Airways Malignancies.

Dr. Ben Solomon
Doctor Solomon is a medical oncologist & Professor in the Lung Service and the Head & Neck service at Peter Mac in Australia. He is the Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division.
Doctor Solomon is a medical oncologist & Professor in the Lung Service and the Head & Neck service at Peter Mac in Australia. He is the Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division.

Jill Feldman
Jill Feldman is a lung cancer patient and activist.
Jill was a volunteer, an advocate and past president of LUNGevity.
CoFounder of EGFRResisters
Jill Feldman is a lung cancer patient and activist.
Jill was a volunteer, an advocate and past president of LUNGevity.
CoFounder of EGFRResisters

Dr. Anirban Maitra
Doctor Maitra, is the scientific director of the Pancreatic Cancer Research Center at MD Anderson and co-leader of the Pancreatic Cancer Moon Shot
Doctor Maitra, is the scientific director of the Pancreatic Cancer Research Center at MD Anderson and co-leader of the Pancreatic Cancer Moon Shot

Diane Mapes
Diane is a Patient advocate and a writer for Fred Hutchinson Cancer Research Center covering research, public health, prevention, health disparities and the patient experience.
Diane is a Patient advocate and a writer for Fred Hutchinson Cancer Research Center covering research, public health, prevention, health disparities and the patient experience.

Dr. Christian Rolfo
Doctor Rolfo is the director of the Thoracic Medical Oncology and the Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). He specializes in thoracic oncology, drug development and translational oncology.
Doctor Rolfo is the director of the Thoracic Medical Oncology and the Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). He specializes in thoracic oncology, drug development and translational oncology.

Dr. Kelly Shanahan
Doctor Shanahan is a retired OBGYN and a Metastatic Breast Cancer Patient Advocate
Doctor Shanahan is a retired OBGYN and a Metastatic Breast Cancer Patient Advocate

Dr. Umberto Malapelle
Doctor Malapelle is the Chief Supervisor of Predictive Molecular Pathology Laboratory, of the University of Naples Federico II. He was appointed in December 2015 Assistant Professor in Anatomic Pathology in School of Medicine, University of Naples Federico II.
Currently his main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor.
Doctor Malapelle is the Chief Supervisor of Predictive Molecular Pathology Laboratory, of the University of Naples Federico II. He was appointed in December 2015 Assistant Professor in Anatomic Pathology in School of Medicine, University of Naples Federico II.
Currently his main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor.

Dr. Nicole Kuderer
Doctor Kuderer is Faculty, Division of Hematology, Department of Medicine, University of Washington Medical Center. Duke Comprehensive Cancer Center.
Doctor Kuderer is Faculty, Division of Hematology, Department of Medicine, University of Washington Medical Center. Duke Comprehensive Cancer Center.

Dee Sparcio
Ovarian Cancer survivor and Patient Advocate
Ovarian Cancer survivor and Patient Advocate

Dr. Giuseppe Curigliano
Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy.
Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy.

Dr. Jesus Anampa
Doctor Anampa is an Assistant Professor of Clinical Medicine in the Department of Medical Oncology at Albert Einstein College of Medicine/ Montefiore Medical Center.
Doctor Anampa is an Assistant Professor of Clinical Medicine in the Department of Medical Oncology at Albert Einstein College of Medicine/ Montefiore Medical Center.

Dr. Bartomeu Massuti
Head of the department of medical oncology at Alicante University Hospital and associate professor at the Universidad Miguel Hernandez de Elche. Focus on Thoracic Oncology
Head of the department of medical oncology at Alicante University Hospital and associate professor at the Universidad Miguel Hernandez de Elche. Focus on Thoracic Oncology

Dr. Bettina Ryll
Doctor Ryll is A Cancer Misson Board member at the European Commission, Founder of the Melanoma Patient Network Europe and, until December 2018, Chair of the ESMO Patient Advocates Working Group.
Doctor Ryll is A Cancer Misson Board member at the European Commission, Founder of the Melanoma Patient Network Europe and, until December 2018, Chair of the ESMO Patient Advocates Working Group.

Dr. Percy Lee
Professor and Section Chief of the Thoracic Radiation Oncology Section in the Department of Radiation Oncology at The University of Texas M.D. Anderson Cancer Center.
Professor and Section Chief of the Thoracic Radiation Oncology Section in the Department of Radiation Oncology at The University of Texas M.D. Anderson Cancer Center.

Dr. Tian Zhang
Assistant Professor of Medicine. Member of the Duke Cancer Institute.
Focus on GU Oncology
Assistant Professor of Medicine. Member of the Duke Cancer Institute.
Focus on GU Oncology

Dr. Manju George
Doctor George is a Patient Advocate with post-doctoral training and research experience in Cell and Cancer Biology and is the Scientific Director at Colontown/Paltown
Doctor George is a Patient Advocate with post-doctoral training and research experience in Cell and Cancer Biology and is the Scientific Director at Colontown/Paltown

Dr. Bishoy Faltas
Dr. Bishoy Morris Faltas is an Assistant Professor of Medicine at Weill Cornell Medicine and an Assistant Attending in the Genitourinary Oncology Program within the Division of Hematology & Medical Oncology. He completed his Hematology and Medical Oncology Fellowship at Weill Cornell, along with a research fellowship in Dr. Mark A. Rubin's laboratory, where he studied clonal evolution and the neoantigenic structure of platinum-resistant bladder cancer. As a physician-scientist, Dr. Faltas focuses on the molecular profiles of metastatic platinum-resistant urothelial bladder cancer, investigating mechanisms of mutagenesis, drug resistance, and conducting immunogenomic studies of urological malignancies. His research aims to identify potential drug targets to inform therapeutic clinical trials, leveraging genomic approaches to tailor treatment based on the unique molecular profiles of individual cancers as part of The Caryl and Israel Englander Institute for Precision Medicine.
Dr. Bishoy Morris Faltas is an Assistant Professor of Medicine at Weill Cornell Medicine and an Assistant Attending in the Genitourinary Oncology Program within the Division of Hematology & Medical Oncology. He completed his Hematology and Medical Oncology Fellowship at Weill Cornell, along with a research fellowship in Dr. Mark A. Rubin's laboratory, where he studied clonal evolution and the neoantigenic structure of platinum-resistant bladder cancer. As a physician-scientist, Dr. Faltas focuses on the molecular profiles of metastatic platinum-resistant urothelial bladder cancer, investigating mechanisms of mutagenesis, drug resistance, and conducting immunogenomic studies of urological malignancies. His research aims to identify potential drug targets to inform therapeutic clinical trials, leveraging genomic approaches to tailor treatment based on the unique molecular profiles of individual cancers as part of The Caryl and Israel Englander Institute for Precision Medicine.

Ms Janice Cowden
Research patient advocate living w/ Stage IV Metastatic Breast Cancer.
Research patient advocate living w/ Stage IV Metastatic Breast Cancer.

Ms Patty Spears
Research Manager, Patient Advocates for Research Council
Office of Clinical & Translational Research in Oncology
Patty Spears provides scientific leadership and guidance to advance OCTR translational trials and data management of the Alliance for Clinical Trials in Oncology breast cancer research trials.
UNC Cancer Center
Research Manager, Patient Advocates for Research Council
Office of Clinical & Translational Research in Oncology
Patty Spears provides scientific leadership and guidance to advance OCTR translational trials and data management of the Alliance for Clinical Trials in Oncology breast cancer research trials.
UNC Cancer Center
Dr. Elisa Agostinetto
Medical Research Fellow at the Institute Jules Bordet in Brussels, Belgium, with a medical degree from the University of Udine, Italy, and specialized training in Milan. Her primary focus is on breast cancer, where she contributes as an investigator for the EORTC Breast Cancer Working Group and serves on the Steering Committee for Young Cancer Professionals. She is involved in the AURORA exploratory trial to study the molecular characteristics of metastatic breast cancer and has conducted research on adjuvant therapies for HER2-positive breast cancer, while also investigating treatment impacts on young patients and exploring immunotherapy potential for triple-negative breast cancer . |

Dr. Allison Betof Warner
Board-certified medical oncologist and Assistant Professor in the Department of Medicine's Division of Medical Oncology, specializing in cutaneous oncology. She is the Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program. A pioneer in tumor infiltrating lymphocyte (TIL) therapy for immunotherapy-refractory melanoma, her clinical interests include advanced melanoma, immunotherapy, and cellular therapies. As leader of the Melanoma & Cutaneous Oncology Clinical Research Group, she investigates tumor responses to immunotherapy and has led numerous clinical trials. Dr. Betof Warner is recognized for her expertise in central nervous system metastases and collaborates internationally across various specialties, receiving funding and awards from prominent organizations like ASCO and NIH.
Board-certified medical oncologist and Assistant Professor in the Department of Medicine's Division of Medical Oncology, specializing in cutaneous oncology. She is the Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program. A pioneer in tumor infiltrating lymphocyte (TIL) therapy for immunotherapy-refractory melanoma, her clinical interests include advanced melanoma, immunotherapy, and cellular therapies. As leader of the Melanoma & Cutaneous Oncology Clinical Research Group, she investigates tumor responses to immunotherapy and has led numerous clinical trials. Dr. Betof Warner is recognized for her expertise in central nervous system metastases and collaborates internationally across various specialties, receiving funding and awards from prominent organizations like ASCO and NIH.